Business Insider

Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal

SHANGHAI, Sept. 16, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement ...
Nasdaq

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually

NEW YORK--(BUSINESS WIRE)-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has ...
Monthly Prescribing Reference

Fixed-Dose Combo Mydcombi Ophthalmic Spray Approved to Induce Mydriasis

Credit: Getty Images. MydCombi is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist. The Food and Drug Administration (FDA) has ...
Monthly Prescribing Reference

Ryzumvi Approved for Reversal of Pharmacologically-Induced Mydriasis

Credit: Shutterstock. Ryzumvi is a preservation-free eye drop formulation of phentolamine mesylate, an alpha adrenergic blocker. The Food and Drug Administration (FDA) has approved Ryzumvi™ ...
Healio

Drop speeds reversal of pharmacologically induced mydriasis

Please provide your email address to receive an email when new articles are posted on . Nyxol, an alpha 1/2 antagonist eye drop, helped reverse the effects of pharmacologically induced mydriasis in ...
Nasdaq

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis

FARMINGTON HILLS, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing ...
Healio

FDA accepts NDA for Nyxol drops for mydriasis reversal

Please provide your email address to receive an email when new articles are posted on . The FDA accepted a new drug application for Nyxol for the reversal of pharmacologically induced mydriasis, ...
Fox2Now St. Louis

If Approved Later This Year, Nyxol Could be the Only Commercially Available Eye Drop for Reversal of Dilation

FARMINGTON HILLS, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing ...